Related references
Note: Only part of the references are listed.Reliability and validity of the King's Health Questionnaire for lower urinary tract symptoms in both genders
Kikuo Okamura et al.
BJU INTERNATIONAL (2009)
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin
Peter K. Sand et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2009)
Measuring urgency in clinical practice
Roger R. Dmochowski et al.
WORLD JOURNAL OF UROLOGY (2009)
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use - A 12-week, open-label, post-marketing surveillance study
Martin C. Michel et al.
DRUG SAFETY (2008)
The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis
Christopher R. Chapple et al.
EUROPEAN UROLOGY (2008)
A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
Giacomo Novara et al.
EUROPEAN UROLOGY (2008)
Development and Validation of the Short Form of a Urinary Quality of Life Questionnaire: SF-Qualiveen
Veronique Bonniaud et al.
JOURNAL OF UROLOGY (2008)
A simple validated scale to measure urgency
Salah Al-Buheissi et al.
JOURNAL OF UROLOGY (2008)
Terazosin therapy for patients with female lower urinary tract symptoms: A randomized, double-blind, placebo controlled trial
Bee Yean Low et al.
JOURNAL OF UROLOGY (2008)
Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire
Elisabeth Piault et al.
NEUROUROLOGY AND URODYNAMICS (2008)
Urgency assessment in the evaluation of overactive bladder (OAB)
Jonathan S. Starkman et al.
NEUROUROLOGY AND URODYNAMICS (2008)
Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients
Martin C. Michel et al.
NEUROUROLOGY AND URODYNAMICS (2007)
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study
Debra E. Irwin et al.
EUROPEAN UROLOGY (2006)
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder
Christopher R. Chapple
EXPERT OPINION ON PHARMACOTHERAPY (2006)
The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder
Karin S. Coyne et al.
EUROPEAN UROLOGY (2006)
The overactive bladder-symptom composite score: A composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder
N Zinner et al.
JOURNAL OF UROLOGY (2005)
Validation of the Urgency Perception Scale
L Cardozo et al.
BJU INTERNATIONAL (2005)
The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects
CR Chapple et al.
BJU INTERNATIONAL (2005)
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder
F Haab et al.
EUROPEAN UROLOGY (2004)
Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial
V Khullar et al.
UROLOGY (2004)
Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine
R Freeman et al.
OBSTETRICS AND GYNECOLOGY (2003)
The standardisation of terminology of lower urinary tract function: Report from the of the International Standardisation Sub-Committee Continence Society
P Abrams et al.
NEUROUROLOGY AND URODYNAMICS (2002)
How widespread are the symptoms of an overactive bladder and how are they managed?: A population-based prevalence study
I Milsom et al.
BJU INTERNATIONAL (2001)
Treatment satisfaction of patients with lower urinary tract symptoms: Randomised controlled trials vs. real life practice
MC Michel et al.
EUROPEAN UROLOGY (2000)
Share Paper
